News
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
Inogen Expands Its Respiratory Product Portfolio with Acquisition of Physio-Assist
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the company has entered into a definitive
Simulations Plus Releases ADMET Predictor® 11
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the release of ADMET Predictor®
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 21,000,000 shares of its
First Half of 2023 Sees ICON Recognised for CRO Excellence, Alongside Industry Awards as an Employer of Choice and for Its Creative and Digital Services
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has received positive recognition from leading business and industry organisations as a leading
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business
Chemed To Report Second-Quarter 2023 Earnings July 26, Related Conference Call To Be Held On July 27
Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2023, on Wednesday, July 26, 2023, following the close of trading on the
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Delaware District Court Permits NanoString’s Counterclaims that 10x Genomics and Harvard Violated the Antitrust Laws
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, provided comments on yesterday’s order of the United States District
Agilent Achieves Great Place to Work® Certification
Agilent Technologies Inc. (NYSE: A) today announced the company has achieved certification as a Great Place to Work®. The recognition reflects Agilent's commitment to creating a positive work
Agilent Announces Gen6 Software for BioTek Line of Microplate Readers
Agilent Technologies Inc. (NYSE: A) today announced the launch of new Gen6 software for all Agilent BioTek detection instruments. Featuring a broad range of prebuilt experiment templates for common
NanoString Provides Preliminary Financial and Operational Highlights for Second Quarter of 2023
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for
Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in the UK
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis
Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced that Ilumetri® (tildrakizumab) significantly improved wellbeing in patients with
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and development, today reported financial results for its
Acadia Healthcare Announces Date for Second Quarter 2023 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2023 results on Thursday, July 27, 2023, after the close of the market. Acadia will conduct a
Dexcom Schedules Second Quarter 2023 Earnings Release and Conference Call for July 27, 2023 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, July 27, 2023. Management will hold a conference call